## ADMA: ADMA Biologics, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.34 indicates fundamental undervaluation. Quality metrics strong (ROE 63%, ROA 22%). Caution: overbought RSI (77).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($18.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump**
- Source: Simply Wall Street | 20251203T051007 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has experienced a 25% price jump recently, though its share price is still down 2.7% over the last twelve months. The company's P/E ratio of 22x is higher than the market average of 18x, which is attributed to its impressive earnings growth of 198% in the last year and a projected 21% annual EPS increase over the next three years. This strong growth outlook makes shareholders comfortable with the elevated P/E ratio.

**2. ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump**
- Source: Sahm | 20251203T051007 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has experienced a 25% price jump in the last month, but its shares are still down 2.7% over the past year. The company's P/E ratio of 22x is higher than the U.S. market average, but this is attributed to its impressive earnings growth of 198% last year and anticipated EPS climb of 21% annually over the next three years, significantly outperforming the market forecast of 11%. Despite past mixed results, analysts are optimistic about its future growth, justifying the higher P/E.

**3. Legal & General Group Plc Acquires 37,699 Shares of ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251202T220846 | Neutral | Relevance: 100%
- Legal & General Group Plc has increased its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 5.6%, acquiring an additional 37,699 shares, bringing its total holdings to 713,576 shares valued at approximately $12.99 million. This move comes despite a recent downgrade of ADMA Biologics by Weiss Ratings from a "buy" to a "hold" rating. The company reported strong financial results in its last quarter, with EPS of $0.16 and revenue of $134.22 million, and maintains a "Buy" consensus rating among analysts with a target price of $28.50.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.08M) |
| Sells | 2 ($0.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Elevated short interest (9.7%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 21.4x attractive for 57% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.6B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 21.4 |
| Current P/E | 33.5 |
| YoY Growth | 56.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 16.6% to 15.2% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (15.2% > 10.0%), caution on chasing. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 17.6% shows strong absolute momentum above own 20MA. Outperforming sector by 16.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 77, risk of mean reversion. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 15.25% (CS: 98) | Strong |
| RSI_14 | 76.8 | Overbought |
| MACD Histogram | 0.33 | Bullish |
| vs SMA20 | 1.176x | Above |
| vs SMA50 | 1.273x | Above |
| vs SMA200 | 1.120x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $20.11
- **Stop Loss:** $18.57 (7.7% risk)
- **Target:** $23.19 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 324
- **Position Value:** $6,515.64
- **Portfolio %:** 6.52%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*